That negative information should be considered in the context of the personal testimony of patients such as Wilkinson about the efficacy of the company's therapy. It is possible that the FDA could be right about Celltex's technical deficiencies and the therapy still be effective. But patients should investigate whether such negative information exists about the therapy before going ahead. After all, it's their health and lives that are at stake.